Research & Literature

Palliative care for patients with end-stage liver disease.

Larson AM

Current gastroenterology reports 2015; (17(5)):440 doi:10.1007/s11894-015-0440-6.

The Prescription Pattern of Acetaminophen and Non-Steroidal Anti-Inflammatory Drugs in Patients with Liver Cirrhosis.

Hong YM, Yoon KT, Heo J, et al.

Journal of Korean medical science 2016; (31(10)):1604-10 doi:10.3346/jkms.2016.31.10.1604.

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.

Dulai PS, Singh S, Patel J, et al.

Hepatology (Baltimore, Md.) 2017; (65(5)):1557-1565 doi:10.1002/hep.29085.

Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.

Castera L, Friedrich-Rust M, Loomba R

Gastroenterology 2019; (156(5)):1264-1281.e4 doi:10.1053/j.gastro.2018.12.036.

Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.

Taylor RS, Taylor RJ, Bayliss S, et al.

Gastroenterology 2020; (158(6)):1611-1625.e12 doi:10.1053/j.gastro.2020.01.043.

Nonalcoholic Steatohepatitis: A Review.

Sheka AC, Adeyi O, Thompson J, et al.

JAMA 2020; (323(12)):1175-1183 doi:10.1001/jama.2020.2298.

Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.

Selvaraj EA, Mózes FE, Jayaswal ANA, et al.

Journal of hepatology 2021; (75(4)):770-785 doi:10.1016/j.jhep.2021.04.044.

Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes.

Alhinai A, Patel K, Fonseca VA, Sebastiani G

Journal of diabetes and its complications 2021; (35(9)):107978 doi:10.1016/j.jdiacomp.2021.107978.

Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases.

Eslam M, Ahmed A, Després JP, et al.

The lancet. Gastroenterology & hepatology 2021; (6(9)):743-753 doi:10.1016/S2468-1253(21)00132-1.

Management of Decompensated Cirrhosis and Associated Syndromes.

Chandna S, Zarate ER, Gallegos-Orozco JF

The Surgical clinics of North America 2022; (102(1)):117-137 doi:10.1016/j.suc.2021.09.005.

Why paracetamol (acetaminophen) is a suitable first choice for treating mild to moderate acute pain in adults with liver, kidney or cardiovascular disease, gastrointestinal disorders, asthma, or who are older.

Alchin J, Dhar A, Siddiqui K, Christo PJ

Current medical research and opinion 2022; (38(5)):811-825 doi:10.1080/03007995.2022.2049551.

Treatment of refractory ascites: Current strategies and new landscape of non-selective beta-blockers.

Vidal González D, Pérez López KP, Vera Nungaray SA, Moreno Madrigal LG

Gastroenterologia y hepatologia 2022; (45(9)):715-723 doi:10.1016/j.gastrohep.2022.02.004.

Negative impact of the pandemic on hospital admissions, morbidity and early mortality for acute cirrhosis decompensation.

Gananandan K, Phillips A, Chikhlia A, et al.

BMJ open gastroenterology 2023; (10(1)) doi:10.1136/bmjgast-2022-001071.

Paracetamol (Acetaminophen)-associated SJS, TEN, AGEP, and DRESS Syndromes - A Narrative Review.

Pakkir Maideen NM, Barakat IR, Jumale AH

Current drug safety 2024; (19(2)):218-223 doi:10.2174/1574886318666230505144014.

Beta-adrenergic blockade in cirrhosis - harmful or helpful?

Møller S, Danielsen KV, Nabilou P, et al.

Expert review of gastroenterology & hepatology 2023; (17(6)):519-529 doi:10.1080/17474124.2023.2215428.

A multisociety Delphi consensus statement on new fatty liver disease nomenclature.

Rinella ME, Lazarus JV, Ratziu V, et al.

Journal of hepatology 2023; (79(6)):1542-1556 doi:10.1016/j.jhep.2023.06.003.

Severe Acetaminophen Toxicity From the Use of Oxycodone-Acetaminophen With Normal Liver Function Tests and a Completely Asymptomatic Course of Hospitalization.

Haider MA, Gheit YS, Nagi T, et al.

ACG case reports journal 2023; (10(8)):e01126 doi:10.14309/crj.0000000000001126.

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity.

Kim GA, Moon JH, Kim W

Clinical and molecular hepatology 2023; (29(4)):831-843 doi:10.3350/cmh.2023.0277.

Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor.

Platek AE, Szymanska A

Clinical and experimental hepatology 2023; (9(3)):187-192 doi:10.5114/ceh.2023.130744.

Natural history of metabolic dysfunction-associated steatotic liver disease.

Lekakis V, Papatheodoridis GV

European journal of internal medicine 2024; (122()):3-10 doi:10.1016/j.ejim.2023.11.005.

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.

Harrison SA, Bedossa P, Guy CD, et al.

The New England journal of medicine 2024; (390(6)):497-509 doi:10.1056/NEJMoa2309000.

Acute and non-acute decompensation of liver cirrhosis.

McCoy MS, Angeli P, Trebicka J

Liver international : official journal of the International Association for the Study of the Liver 2025; (45(3)):e15861 doi:10.1111/liv.15861.

Resmetirom: First Approval.

Keam SJ

Drugs 2024; (84(6)):729-735 doi:10.1007/s40265-024-02045-0.

Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?

Huttasch M, Roden M, Kahl S

Metabolism: clinical and experimental 2024; (157()):155937 doi:10.1016/j.metabol.2024.155937.

EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).

, ,

Journal of hepatology 2024; (81(3)):492-542 doi:10.1016/j.jhep.2024.04.031.

EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

, ,

Obesity facts 2024; (17(4)):374-444 doi:10.1159/000539371.

EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.

, ,

Diabetologia 2024; (67(11)):2375-2392 doi:10.1007/s00125-024-06196-3.

Resmetirom: The First Food and Drug Administration-Approved Medication for Nonalcoholic Steatohepatitis (NASH).

Guirguis E, Dougherty J, Thornby K, et al.

The Annals of pharmacotherapy 2025; (59(2)):162-173 doi:10.1177/10600280241259528.

Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease.

Tincopa MA, Loomba R

Seminars in liver disease 2024; (44(3)):287-299 doi:10.1055/s-0044-1788277.

Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis.

Noureddin M, Charlton MR, Harrison SA, et al.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2024; (22(12)):2367-2377 doi:10.1016/j.cgh.2024.07.003.

NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review.

Sergi CM

International journal of molecular sciences 2024; (25(15)) doi:10.3390/ijms25158462.

Diagnostics and omics technologies for the detection and prediction of metabolic dysfunction-associated steatotic liver disease-related malignancies.

Lan T, Tacke F

Metabolism: clinical and experimental 2024; (161()):156015 doi:10.1016/j.metabol.2024.156015.

Management strategies for metabolic dysfunction-associated steatotic liver disease (MASLD).

Alkhouri N, Noureddin M

The American journal of managed care 2024; (30(9 Suppl)):S159-S174 doi:10.37765/ajmc.2024.89635.

Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD).

Iturbe-Rey S, Maccali C, Arrese M, et al.

Atherosclerosis 2025; (400()):119053 doi:10.1016/j.atherosclerosis.2024.119053.

Comparison of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter Protein-2 Inhibitors on Treating Metabolic Dysfunction-Associated Steatotic Liver Disease or Metabolic Dysfunction-Associated Steatohepatitis: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials.

Xu R, Liu B, Zhou X

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2025; (31(4)):521-535 doi:10.1016/j.eprac.2024.11.017.

Understanding MASH: An Examination of Progression and Clinical Outcomes by Disease Severity in the TARGET-NASH Database.

Luthra R, Sheth A

Advances in therapy 2025; (42(2)):1165-1195 doi:10.1007/s12325-024-03085-4.

Integrated Management of Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1RAs.

Theodorakis N, Nikolaou M

Biomedicines 2025; (13(1)) doi:10.3390/biomedicines13010135.

Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease.

Yip TC, Lee HW, Lin H, et al.

Journal of hepatology 2025; (83(2)):304-314 doi:10.1016/j.jhep.2025.01.014.

Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study.

Caussy C, Vergès B, Leleu D, et al.

Diabetes care 2025; (48(6)):877-886 doi:10.2337/dc24-2075.

Persisting challenges in the early detection of hepatocellular carcinoma.

Arvind A, Redmon K, Singal AG

Expert review of anticancer therapy 2025; 1-12 doi:10.1080/14737140.2025.2467184.

Impact of Weight Loss on Metabolic Dysfunction Associated Steatohepatitis and Hepatic Fibrosis.

Takawy MW, Abdelmalek MF

Current diabetes reports 2025; (25(1)):23 doi:10.1007/s11892-025-01579-1.

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association.

Cusi K, Abdelmalek MF, Apovian CM, et al.

Diabetes care 2025; (48(7)):1057-1082 doi:10.2337/dci24-0094.

A Gastroenterologist's Approach to Improving Metabolic Health in MASLD.

Abdulrazzak E, Alabdul Razzak I, Noureddin M, Trivedi HD

Journal of clinical gastroenterology 2025; (59(8)):713-724 doi:10.1097/MCG.0000000000002210.

Predicting Esophageal Varices and Varices Needing Treatment in Compensated Advanced Chronic Liver Disease.

Thandassery RB, John N, Mashal FA, et al.

Digestive diseases and sciences 2025; (70(11)):3679-3685 doi:10.1007/s10620-025-09193-7.

Alcohol Consumption and Liver Metabolism in the Era of MASLD: Integrating Nutritional and Pathophysiological Insights.

Acierno C, Barletta F, Caturano A, et al.

Nutrients 2025; (17(13)) doi:10.3390/nu17132229.

Metabolic dysfunction-associated steatotic liver disease management in Saudi Arabia: A modified Delphi-based adaptation of international standards.

Abaalkhail F, Sanai FM, AlSwat K, et al.

Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association 2026; (32(2)):104-120 doi:10.4103/sjg.sjg_199_25.

Efficacy and Safety of Vitamin E in Adults With Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Hussaini H, Kaur Dhanjal M, Mohammed Abdul RH, et al.

Cureus 2025; (17(7)):e88949 doi:10.7759/cureus.88949.

MASH: the nexus of metabolism, inflammation, and fibrosis.

Steinberg GR, Carpentier AC, Wang D

The Journal of clinical investigation 2025; (135(18)).

Interaction of inflammation and portal hypertension in cirrhosis progression.

Costa D, Trebicka J, Ripoll C, et al.

Nature reviews. Gastroenterology & hepatology 2025; (22(12)):846-865 doi:10.1038/s41575-025-01107-2.

Diet and Lifestyle Interventions in Metabolic Dysfunction-Associated Fatty Liver Disease: A Comprehensive Review.

Sheikh MY, Younus MF, Shergill A, Hasan MN

International journal of molecular sciences 2025; (26(19)) doi:10.3390/ijms26199625.

Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review.

Tilg H, Petta S, Stefan N, Targher G

JAMA 2026; (335(2)):163-174 doi:10.1001/jama.2025.19615.

Utility of Biomarker Panels in the Surveillance and Monitoring of Hepatocellular Carcinoma: Consensus Statements from an International Delphi Panel.

Singal AG, Toyoda H, Tanwandee T, et al.

Liver cancer 2025; doi:10.1159/000550100.

Impact of multidisciplinary steatotic liver disease management on bariatric surgery referral and clinical outcomes: A retrospective cohort study.

Schwartz AW, Park EY, Ilagan-Ying YC, et al.

World journal of hepatology 2026; (18(1)):113753 doi:10.4254/wjh.v18.i1.113753.

Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart-liver co-management.

Zhou XD, Lazarus JV, Krittanawong C, et al.

The lancet. Gastroenterology & hepatology 2026; (11(6)):521-537 doi:10.1016/S2468-1253(25)00323-1.

MASH in Type 2 Diabetes: Pathophysiology, Diagnosis, and Therapeutic Management-A Narrative Review.

Ştefan AG, Mitrea A, Clenciu D, et al.

Medicina (Kaunas, Lithuania) 2026; (62(2)) doi:10.3390/medicina62020325.

Metabolic Dysfunction-Associated Steatotic Liver Disease and Atherosclerotic Cardiovascular Disease: Shared Pathophysiology, Biomarkers, and Emerging Therapeutic Strategies.

Drogy MS, Minto ST, Frishman WH

Cardiology in review 2026; doi:10.1097/CRD.0000000000001259.

Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease.

Younossi ZM, Kalligeros M, Wong VW, et al.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2026; (24(9)):2333-2347 doi:10.1016/j.cgh.2026.03.030.

Metabolic and bariatric surgery in MAFLD: a meta-analysis of endocrine outcomes, fibrosis remission, and postoperative complications.

Kopanos S, Hoyer A, Stoye FV, et al.

Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery 2026; (22(7)):806-817 doi:10.1016/j.soard.2026.03.020.

Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach.

Kim BK

The Kaohsiung journal of medical sciences 2026; e70227 doi:10.1002/kjm2.70227.

Evidence-Based Clinical Practice Guidelines for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 2026.

Akuta N, Kogiso T, Ikejima K, et al.

Hepatology research : the official journal of the Japan Society of Hepatology 2026; (56(6)):887-902 doi:10.1111/hepr.70188.

GLP-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes.

Amorim Moreira Alves G, Teranishi M, Majumdar R, et al.

Chronic diseases and translational medicine 2026; (12(2)):85-99 doi:10.1002/cdt3.70048.

The Multifaceted Roles of Gut Microbiota and Their Metabolites in Metabolic Dysfunction-associated Steatotic Liver Disease: A Literature Review.

Zhang Y, Wang D, Zhuang B, et al.

Journal of clinical and translational hepatology 2026; (14(5)):554-564 doi:10.14218/JCTH.2025.00605.

Metabolic Dysfunction-Associated Steatotic Liver Disease: Current Diagnostic Pathways, Noninvasive Fibrosis Assessment, and Therapeutic Strategies.

Bazan A, Plichta O, Radzinska N

Cureus 2026; (18(5)):e108965 doi:10.7759/cureus.108965.

Longitudinal Validation of Clinical Care Pathways for Metabolic Dysfunction-Associated Steatotic Liver Disease in a Prospective Cohort of Individuals With Type 2 Diabetes.

Dounel J, Díaz LA, Bettencourt R, et al.

Gastro hep advances 2026; (5(9)):101022 doi:10.1016/j.gastha.2026.101022.

Pharmacological treatment of MASH.

Stefan N, Targher G

Diabetologia 2026; (69(11)):3148-3161 doi:10.1007/s00125-026-06796-1.

Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations.

Newsome JS

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians 2026; 87551225261466571 doi:10.1177/87551225261466571.

Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction-Associated Steatohepatitis-Reanalysis of Fibrosis Stage 2-3 Subset.

Mironova M, Padmanabhan K, Schneider D, et al.

Alimentary pharmacology & therapeutics 2026; (64(7)):919-929 doi:10.1111/apt.70888.

Sequential FIB-4-based testing limits detection of fibrotic MASLD despite optimized ELF thresholds.

Allen AM, Bobek OJ, Canning RE, et al.

Hepatology communications 2026; (10(9)) doi:10.1097/HC9.0000000000001012.

Risk stratification of MASLD/MASH in type 2 diabetes: a pragmatic endocrinology outpatient pathway.

Cai Y, Zeng F, Liu C

Frontiers in endocrinology 2026; (17()):1922533 doi:10.3389/fendo.2026.1922533.

Metabolic dysfunction-associated steatotic liver disease: A primer for primary care NPs.

Casler K, Chaney A

The Nurse practitioner 2026; (51(9)):20-30 doi:10.1097/01.NPR.0000000000000471.

⁠From liver to cardiovascular system: the MASLD-ASCVD continuum.

Boccatonda A, Bray A, Marozzi MS, et al.

Internal and emergency medicine 2026; doi:10.1007/s11739-026-04497-6.

Risk assessment in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-related liver disease: current approaches and future directions.

Lin H, Wang H, Yang K, et al.

Clinical and molecular hepatology 2026; (32(Suppl)):e2026.0398 doi:10.3350/cmh.2026.0398.

Prognostic value of liver histology in steatotic liver disease: a systematic literature review and meta-analysis.

Barritt AS, Qasim A, Kim Y, et al.

Journal of comparative effectiveness research 2026; (15(10)):e260148 doi:10.57264/cer-2026-0148.

Lipid Metabolic Reprogramming and Bioactive Lipid Signaling in MASLD: Molecular Mechanisms, Pathogenesis and Therapeutic Opportunities.

Ábel T, Csobod Csajbókné É

International journal of molecular sciences 2026; (27(17)) doi:10.3390/ijms27177805.